The COVID-19 virus is evolving and vaccines are adapting in 2025
By mid-2025, COVID-19 has entered an endemic phase marked by the constant evolution of the virus and uneven immunity across populations. SARS-CoV-2 continues to mutate, primarily in the spike protein, which allows it to bind more effectively to human cells and evade immune defenses. This adaptability has given rise to variants such as NB.1.8.1, LP.8.1, and XFG, which are spreading rapidly due to their increased transmissibility and resistance to existing antibodies.
Between late 2024 and mid-2025, epidemiological data show significant fluctuations in case numbers, with regional peaks in hospitalizations and a rise in positive tests. For example, test positivity rates increased from 2% to 11% between February and May 2025, a level not seen since the summer of 2024. The Americas, Europe, and Southeast Asia experienced the most pronounced increases, reflecting differences in population immunity, variant circulation, and surveillance capacities.
The dominant variants have changed rapidly during this period. In January 2025, XEC and LP.8.1 together accounted for nearly 50% of monitored strains, while JN.1 and KP.3.1.1 were in decline. By March, LP.8.1 had become the majority variant, only to be overtaken in June by NB.1.8.1 and XFG, which eventually dominated with over 30% each. These variants share key mutations in the spike protein, such as F456L or Q493E, which enhance their ability to evade neutralizing antibodies. XFG, for example, combines modifications that strengthen both immune evasion and viral stability, explaining its rapid global spread.
Vaccines remain an essential tool in limiting the severity of the disease. Messenger RNA formulations, such as those adapted to the JN.1 and KP.2 variants, show a strong neutralizing response against the strains circulating in 2025. However, their effectiveness wanes over time, especially in the elderly. Viral vector or protein subunit vaccines, although initially less effective, provide lasting protection through a robust cellular response, particularly via T lymphocytes. These cells, which directly target infected cells, play a key role in long-term immune memory.
Booster strategies, particularly those combining different vaccine technologies, have proven effective in maintaining broad and durable immunity. For example, a booster dose with an mRNA vaccine following an initial viral vector vaccination significantly improves the immune response, both in terms of antibodies and T cells. This allows for better resistance to new variants, even as their ability to evade existing defenses continues to improve.
Global genomic surveillance, with over 17 million shared sequences, has enabled tracking of these developments and the adaptation of public health responses. Nevertheless, regional disparities in access to healthcare and vaccines, along with the gradual decline in immunity, highlight the need to strengthen health infrastructures and develop next-generation vaccines. These new vaccines should target multiple antigens to provide broader and more durable protection, while also stimulating a T lymphocyte response capable of neutralizing various variants.
Recent observations confirm that the virus continually optimizes its immune evasion mechanisms, while current vaccines, though improved, struggle to maintain complete long-term protection. The combination of these factors makes a global approach essential—one that combines scientific innovation and international cooperation to anticipate future waves and limit the impact of the disease.
Credits
Source Study
DOI: https://doi.org/10.1186/s12982-026-01657-z
Title: SARS-CoV-2 variant dynamics and COVID-19 vaccine effectiveness during global epidemiological changes in mid-2025
Journal: Discover Public Health
Publisher: Springer Science and Business Media LLC
Authors: Risha Haldar; Prolay Halder; Bhaskar Mahanayak